Diversification working, but US aspirations face quota and approval headwinds

Delivered 1265.4 Cr revenue, +13.0% YoY; US stable $68M, Ex-US +17% to $63M

Q1 delivered 60.9%, +60 bps YoY (prior ~60.3%), within target band

Q1 18.2% vs prior >20% guidance; down 130 bps YoY (19.5% approx FY26 run-rate)

Reported PAT ₹165.5 Cr (+56.7% YoY) includes ₹53.4 Cr Pivot Path tax-net gain; operational PAT ₹123.1 Cr (+8% YoY only)

US revenue $68M (Q1 FY27 vs $71M Q4 FY26, stable YoY); acknowledged first 2 quarters will be soft

Ex-US +17% YoY to $63M; Q4 was $70M, Q1 dip due to supply chain timing (expecting recovery)

18.2% margin in Q1 vs prior >20% target; 130 bps YoY compression blamed on ₹13.1 Cr geopolitical costs and freight (+90 bps), but underlying pressure evident

$68M US revenue stable YoY but below growth aspirations; acknowledged first 2 quarters soft, expecting H2 ramp. $375M FY28 target maintained but execution path vague

$63M vs Q4 $70M due to logistics/geopolitical timing; management expects $7M recovery in coming quarters; underlying demand healthy

5% of US revenue after 1.5 years of investment; June quota allocation cycle results still pending; December cycle pending, creating uncertainty

Five levers: controlled substances (quota ramp), new channels, new geographies/partnerships, product launches (10 planned for FY27), OTC portfolio. First 2 quarters soft, bulk of launches H2-focused. Groundwork laid, confidence in reaching target.

Current net debt ₹1,424.6 Cr. With continued delivery, expect to be debt-neutral in 2–3 years. Debt reduction masked by rupee depreciation (INR82 → INR95–97 on legacy debt). Reduced ₹3 Bn debt last year but FX hedging not visible.

No revenue loss from freight. Supply chain disruptions caused timing delays (elongated supply); Ex-US impacted but temporary. Expect recovery in coming quarters.

B2C markets: UK, Nordics, South Africa, Africa (Francophone + Kenya). B2B: Europe, Australia. Third category: LATAM, MENA, APAC (regulatory filing in progress, new dollars FY28–29). Margins improving vs US. Broad-based, expect to mirror company average growth next 1.5–2 years.

Five/six levers contribute similarly: OTC (green shoots soon), controlled substances (post-1.5yr history ramp), 100+ products queued for systematic launch from Q2, new specialty channels (progress made), partnerships in Canada/geographies. No granular breakdown given.

Q1 $63M corresponds to Q3 prior year (not a miss, growth evident). $7M Q4 shortfall from logistics/geopolitical issues; will recover in coming quarters. Sandoz acquisition not in current numbers; expected Q2 close, contribution in H2.

Sold for ₹100 Cr (not ₹125 Cr). GCC business; two revenue streams (third-party & captive). Don't evaluate on standalone revenue basis. Captive in-house business (low margin). Expect third-party business to drive future PAT benefit in 4–5 years.

First filing advanced review stage; approval expected Q3/Q4 (can shift month-on-month). Second filing 1 month old; 12–15 month review window expected. Will file 5–6 nasal spray programs in next 12–18 months; also working on transdermal patches, thin films. Third product filing expected next few months.

Three domains identified for post-$375M growth: nasal sprays, transdermal patches, thin films. On track to accelerate filings across all three domains over next 1.5–2 years.

10 launches target from now until Mar 31, 2027. Significant increase expected in next year with new approvals. Specific revenue per product not disclosed; focus on six levers for $90M growth bridge, not just launches.

Quota allocations twice yearly (June & December). For first-time entrants, demonstrating past history difficult; need customer backing. Strides at 4 products, 1.5 years demonstration complete. Entire portfolio 5% revenue currently. June cycle results pending, December cycle expected next month. Post-demonstration, ramp-up typically higher in years 2–4.

Annual capex ₹2.5–3 Bn (hard + maintenance + R&D combined). No greenfield planned. Focus on existing factories, high-impact line items. Capex continued at this level ongoing.

Inspection May; reply submitted. 90 days to 3 months for response (end Aug/Sep expected). Does not affect current supplies. Comprehensive response provided. Expect USFDA confirmation by late Aug/Sep. No anticipated revenue impact.

From ~$285M base (FY26); requires $90–115M growth over 8 quarters. Five levers: controlled substances (quota pending), 10 product launches FY27, new channels, new geographies, OTC portfolio. Aspiration-level, not fully quantified

Q1 achieved 60.9%; reaffirmed range maintained despite freight costs 6.2% of revenue. Expansion from mix benefit (Ex-US)

Q1 delivered 18.2%, down 130 bps YoY; ₹13.1 Cr geopolitical costs cited as temporary but structural freight/input pressure evident

No greenfield expansion. Focus on existing factories and high-impact line items. Brownfield-only strategy

$375M FY28 aspiration requires $90–115M growth. Dependent on 5 speculative levers (controlled substances quota, approvals, launches, channels). Controlled substances only 5% contribution after 1.5 years. June quota cycle results pending; December cycle pending.

Q1 EBITDA margin 18.2% vs prior >20% guidance. ₹13.1 Cr geopolitical costs absorbed; freight up 90 bps to 6.2% of revenue. Underlying structural pressure evident despite management's 'resilience' framing.

Bangalore plant FDA inspection in May; observations noted. Response submitted, reply expected end Aug/Sep. No current supply impact but approval delays possible if issues not resolved satisfactorily.

Q1 Ex-US revenue $63M vs Q4 $70M, a $7M shortfall from supply chain disruptions and geopolitical timing issues. Classified as timing, not demand, but recovery execution uncertain.

Pivot Path divestment contributes ₹53.4 Cr (32%) to reported PAT of ₹165.5 Cr. Operational PAT only +8% YoY, masking weaker underlying performance. Risk of market expectation reset on recurring earnings.